Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer-Reference-Cited by-同舟云学术

Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer

Published:2024-04 Issue:sup3 Volume:27 Page:24-33
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

MacDonald Karen¹^ORCID,Pondel Marc²^ORCID,Abraham Ivo¹³⁴⁵⁶^ORCID

Affiliation:

1. Department of Research, Matrix45, Tucson, AZ, USA

2. Department of Medical Affairs, Coherus BioSciences, Inc, Redwood City, CA, USA

3. University of Arizona Cancer Center, Tucson, AZ, USA

4. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

5. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

6. Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, AZ, USA Tucson

Funder

Coherus BioSciences

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2380872

Reference37 articles.

1. National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer stat facts: lung and bronchus cancer; 2022. https://seer.cancer.gov/statfacts/html/lungb.html.

2. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2023. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf.

3. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US

4. Emerging therapeutic agents for advanced non-small cell lung cancer

5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma;Journal of Medical Economics;2024-04